What is Morgan Stanley's price target for IONS?

Morgan Stanley's latest stated price target for Ionis Pharmaceuticals Inc. (IONS) is $62, from its action on Jul 31, 2025.

What is Morgan Stanley's rating on IONS?

Morgan Stanley rates IONS Overweight, a bullish rating, as of Jul 31, 2025.

When did Morgan Stanley last change its view on IONS?

On Jul 31, 2025, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $62.

Analyst firms · Morgan Stanley · IONS

Morgan Stanley IONS price target and rating history

Ionis Pharmaceuticals Inc. (IONS) · Health Care

Morgan Stanley rates Ionis Pharmaceuticals Inc. (IONS) Overweight with a $62 price target, as of its latest action on Jul 31, 2025. It has published 5 rating actions on IONS since July 2021, including 1 upgrade and 1 downgrade. Across 6 firms with a IONS price target in the last 12 months, the median target is $99.50.

Current rating: Overweight
Price target: $62
Median target, all firms: $99.50
Actions on IONS: 5

Morgan Stanley price target on IONS

Morgan Stanley price target on IONS, each point a stated target, July 2021 to July 2025.

Every Morgan Stanley rating on IONS

Jul 31, 2025
UpgradeMorgan Stanley upgrades to Overweight from Equal-Weight, price target $62
Dec 21, 2022
DowngradeMorgan Stanley downgrades to Equal-Weight from Overweight, price target $56 to $40
Sep 9, 2022
ResumeMorgan Stanley resumes coverage at Overweight, price target $57
Oct 12, 2021
ReiterateMorgan Stanley cuts its price target to $31 from $33, keeps Underweight
Jul 16, 2021
ReiterateMorgan Stanley cuts its price target to $33 from $35, keeps Underweight

How other firms rate IONS

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
BMO Capital Markets	Outperform	$66	Oct 22, 2026
UBS	Buy	$88	Oct 15, 2026
Wolfe Research	Peer Perform		Jul 16, 2026
Citigroup	Buy	$115	May 19, 2026
Canaccord Genuity	Buy	$110	Apr 21, 2026
Raymond James	Outperform	$104	Apr 10, 2026
Barclays	Overweight	$95	Jan 28, 2026

Questions about Morgan Stanley and IONS

What is Morgan Stanley's price target for IONS?: Morgan Stanley's latest stated price target for Ionis Pharmaceuticals Inc. (IONS) is $62, from its action on Jul 31, 2025.
What is Morgan Stanley's rating on IONS?: Morgan Stanley rates IONS Overweight, a bullish rating, as of Jul 31, 2025.
When did Morgan Stanley last change its view on IONS?: On Jul 31, 2025, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $62.
How does Morgan Stanley's IONS target compare with other analysts?: Across 6 firms with a IONS price target in the last 12 months, the median target is $99.50.

More IONS rating histories

All Morgan Stanley ratings IONS news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.